CEVI logo

CellaVision AB (publ) Stock Price

OM:CEVI Community·SEK 3.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

CEVI Share Price Performance

SEK 157.20
-53.80 (-25.50%)
SEK 225.00
Fair Value
SEK 157.20
-53.80 (-25.50%)
31.1% undervalued intrinsic discount
SEK 228.00
Fair Value
Price SEK 157.20
AnalystConsensusTarget SEK 228.00

CEVI Community Narratives

AnalystConsensusTarget·
Fair Value SEK 225 30.1% undervalued intrinsic discount

Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative

Trending Discussion

Updated Narratives

CEVI logo

Upcoming Bone Marrow Launch And APAC Expansion Will Unlock Markets

Fair Value: SEK 225 30.1% undervalued intrinsic discount
12 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with flawless balance sheet.

0 Risks
5 Rewards

CellaVision AB (publ) Key Details

SEK 748.5m

Revenue

SEK 231.2m

Cost of Revenue

SEK 517.3m

Gross Profit

SEK 365.8m

Other Expenses

SEK 151.4m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 05, 2026
6.35
69.11%
20.23%
3.2%
View Full Analysis

About CEVI

Founded
1994
Employees
231
CEO
Simon Ostergaard
WebsiteView website
www.cellavision.com

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox for smearing, staining, and analyzing peripheral blood smears. It also provides CellaVision DC-1 for performing blood cell differentials; and CellaVision DM1200 and CellaVision DM9600 to automate and simplify the process of performing blood and body fluid differentials. In addition, the company’s CellaVision Peripheral Blood Application enables laboratories to automate, standardize and simplify morphological examination like peripheral blood smears; CellaVision Advanced RBC Application performs a more comprehensive examination for red blood cell morphology; CellaVision Body Fluid Application is for examination body fluid preparations; CellaVision CellAtlas is an app with morphology experts for series mini lectures on extensive cell image library introduction to cell morphology; CellaVision Remote Review Software removes restrictive geographical constraints from smear review process and performs better; CellaVision Server Software creates a single streamlined workflow within one or multiple testing sites; and CellaVision VET is a veterinary lab. It sells its products to hospitals and commercial laboratories. The company was incorporated in 1994 and is based in Lund, Sweden.

Recent CEVI News & Updates

CellaVision AB (publ) (STO:CEVI) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 09
CellaVision AB (publ) (STO:CEVI) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Recent updates

No updates